Pfizer,
Inc. (NYSE: PFE) has appointed Mikael Dolsten, M.D., PhD, as the President of
Pfizer Worldwide Research and Development, as they complete their integration
of the function following the acquisition of Wyeth.
Top Best Penny Stocks, a leading
financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Dr.
Dolsten previously led the R&D development program at Wyeth and after the
close of the acquisition was named the President of Pfizer’s BioTherapeutics
Research & Development. Prior to joining Wyeth, Dr. Dolston worked in
several leadership positions in R&D at Boehringer Ingelheim and AstraZeneca.
At
Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for
quality, safety and value in the discovery, development and manufacturing of
medicines for people and animals.
Sign up for Top Best Penny Stocks' free
newsletter. To subscribe, enter your e-mail address into the frame at the
bottom of this press release or visit our website
About Us
Top Best Penny Stocks is a leading
stock web site that allows investors and interested parties to research stocks
that are on the move. We also track small cap companies that are on the brink
of a financial breakout. To feature a company on our web site please contact us
at the email listed below.
Please click here to read the full disclaimer
